<DOC>
	<DOCNO>NCT02905110</DOCNO>
	<brief_summary>The goal clinical research study establish safety simultaneous infusion methotrexate etoposide fourth ventricle brain resection cavity patient recurrent malignant posterior fossa brain tumor . These tumor include medulloblastoma , ependymoma , atypical teratoid/rhabdoid tumor malignant brain tumor recurrence progression involve anywhere brain and/or spine . Patients ' disease must originate posterior fossa brain .</brief_summary>
	<brief_title>Methotrexate Etoposide Infusions Into Fourth Ventricle Children With Recurrent Posterior Fossa Brain Tumors</brief_title>
	<detailed_description>If participant eligible take part study , participant surgery place catheter Ommaya reservoir . The Ommaya reservoir catheter system allow drug administer directly part brain . This catheter use infusion methotrexate etoposide directly 4th ventricle brain , 1 4 connect fluid-filled cavity brain . If study doctor think necessary , base location tumor , tumor may also remove participant already anesthesia catheter place . Study Drug Administration : The participant receive twice weekly 4 mg intraventricular methotrexate infusion six consecutive week daily 1 mg intraventricular etoposide infusion five time per week , every 2 week . Etoposide administer week 1 , 3 , 5 . Methotrexate Etoposide infuse though ommaya reservoir catheter directly 4th ventricle brain start minimum 7 day catheter placement surgery . A MRI do confirm adequate cerebrospinal fluid flow . The etoposide infusion last 3-4 minute methotrexate infusion last 3 minute . If participant already Ommaya catheter , methotrexate etoposide begin MRI confirm adequate cerebrospinal fluid flow . Study Visits : Prior first infusion : Medical history review update health record . Physical Neurological exam vital sign do . Blood ( 1 teaspoon ) drawn routine test . A lumbar puncture do . A MRI scan brain spine do check status disease . On day Methotrexate Etoposide Infusion : A neurological exam vital sign do . A Ommaya reservoir tap ( catheter place Ommaya reservoir give methotrexate etoposide infusion . Cerebrospinal fluid ( 1 teaspoon ) collect routine test . Within 7 day complete Final infusion : A neurological exam vital sign do . A lumbar puncture lab work do . A MRI scan brain spine do check status disease . Length Study : The participant receive 12 infusion Methotrexate 4 mg 15 infusion Etoposide 1 mg , long doctor think best interest . The participant longer able receive study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigation study . Methotrexate FDA approve commercially available infusion directly brain tumor . The infusion methotrexate 4th ventricle brain investigational . Etoposide FDA approve commercially available give mouth bloodstream ( intravenously ) never give 4th ventricle brain . The infusion methotrexate etoposide 4th ventricle brain investigational . Up 10 patient enrol study . All enrol Children 's Memorial Hermann Hospital .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>Age 1 21 year time recurrence progression Diagnosis : Patients histologically verified medulloblastoma , ependymoma , atypical teratoid/rhabdoid tumor malignant brain tumor recurrence progression involve anywhere brain and/or spine . To eligible , patient ' disease must originate posterior fossa brain Patient must either measurable evaluable tumor assess MRI brain total spine An implanted catheter fourth ventricle posterior fossa tumor cavity attach Ommaya reservoir agreement one place . A minimum 7 day last dose systemic chemotherapy and/or radiation therapy first infusion chemotherapy fourth ventricle Life expectancy least 12 week opinion PI Lansky score 50 great ≤16 year age Karnofsky score 50 great &gt; 16 year age Existing neurological deficit must stable minimum 1 week prior study enrollment Patients must recover acute toxic effect prior anticancer chemotherapy Adequate bone marrow function define peripheral absolute neutrophil count ( ANC ) ≥ 500/µL , platelet count ≥ 50,000/µL ( transfusion independent ) , hemoglobin ≥ 9.0 gm/dL ( may receive Red Blood Cell transfusion ) Patient patient 's legal representative , parent ( ) , guardian able provide write informed consent . Enrolled another treatment protocol Has receive another investigational chemotherapy agent radiation therapy within 7 day prior intraventricular chemotherapy infusion Evidence untreated infection Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Malignant Neoplasms , Brain</keyword>
</DOC>